Where:
The Colonnade Hotel
120 Huntington Avenue
Boston, Massachusetts 02116
Admission:
$Drug Developers (Earlybird rates & workshops available) USD 2999.00, Academic (Earlybird rates & workshops available) USD 2599.00, Service Providers (Earlybird rates & workshops available) USD 3599.00
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/860126-3?pid=5248
Returning for the 3rd year, the Cell Therapy Analytical Development Summit is the leading industry-defining forum made exclusively for analytical, CMC, QC, and process development experts.
New for 2021, take advantage of two tracks of content showcasing:
• Automated analytical processes to reduce turnaround time
• Strategies to validate novel assays for next generation therapies
• New genomic testing technology to gain a deeper understanding of the cell product
• Experience in navigating regulatory guidelines to reduce delays
… To equip your team with the lessons learned to achieve success in analytical submission from IND through to commercialization.
Learn from analytical trailblazers at bluebird bio, BMS, Kite, Novartis and more to support your efforts in developing safe and effective cell therapies. Download the event guide to learn more.
https://cell-therapy-analytics.com/
14-16 December, 2021
8.30am-5pm EST | Boston, MA
Contact:
[email protected]
Brochure https://go.evvnt.com/860126-0?pid=5248
Tickets https://go.evvnt.com/860126-1?pid=5248
Speakers: Sarah Snykers, Director, Cell Therapy Manufacturing Unit, Celyad, Jas Uppal, Chief Regulatory & Quality Officer, Gamida Cell, Tam Soden, Executive Director & Global Head of Global Quality Control, Kite, a Gilead Company, Knut Niss, Chief Technology Officer, Mustang Bio, Laura Pierce, Biomedical Engineer National, Institute of Standards & Technology, Stuart Macnab, Associate Director, Novartis
Monday, Nov 11, 2024 goes until 11/13
Child Therapy Boston